[ 9 ] Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis[J]. J Am Acad Dermatol, 2005, 53(4): 652-659.
[2]
Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis[J]. Clin Drug Investig, 2010, 30(2): 101-108.
[3]
Baggott JE, Oster RA, Tamura T. Meta-analysis of cancer risk in folic acid supplementation trials[J]. Cancer Epidemiol, 2012, 36(1): 78-81.
[4]
Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies[J]. Clin Dermatol, 2010, 28(1): 88-92.
[5]
Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central-nervous-system toxicity after allogeneic bone-marrow transplantation[J]. N Engl J Med, 1984, 310(8): 527.
[6]
Melnikov S, Mayan H, Uchida S, et al. Cyclosporine metabolic side effects: association with the WNK4 system[J]. Eur J Clin Invest, 2011, 41(10): 1113-1120.
[7]
Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure[J]. Cochrane Database Syst Rev, 2010, 20(1): CD007893.
[8]
Dehesa L, Abuchar A, Nuno-Gonzalez A, et al. The use of cyclosporine in dermatology[J]. J Drug Dermatol, 2012, 11(8): 979.
[9]
Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference[J]. J Am Acad Dermatol, 2010, 62(5): 838-853.
[ 5 ] Flytstr？m I, Stenberg B, Svensson A, et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial[J]. Br J Dermatol, 2008, 158(1): 116-121.
